Avantor (AVTR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Avantor

NYSE•Healthcare•Medical Instruments & Supplies

$17.290.00(0.00%)Market open

Market Cap

$10.87B

P/E

32.2x

P/S

1.6x

P/B

1.9x

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.

How this company scores

GoodMetricSide Score: 64/100

Strongest: Profitability (17/25); weakest: Balance Sheet & Red Flags (15/25).

Profitability17/25

Growth16/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality16/25

Strengths

Rising earningsCash-backed earningsConsistent free cash flowProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 32.2x5y range 13.3x – 65.8x

Currently near its 16-quarter median.

P/S · 1.6x5y range 0.8x – 3.3x

Currently near its 20-quarter median.

P/B · 1.9x5y range 0.9x – 5.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $10.87B

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $6.64B
Q. Revenue: $1.70B
TTM EBITDA: $906.40M
TTM Op. Income: $487.20M
Q. Op. Income: $139.50M
TTM Net Income: $337.20M
Q. Net Income: $203.40M
EPS: $0.3
Shares Out.: $677.10M

$6.64B in TTM revenue grew 0.9% YoY, reaching $1.70B last quarter. TTM EBITDA of $906.40M and TTM operating income of $487.20M show growth is flowing through to the bottom line. TTM net income of $337.20M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 2 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 31.5%
EBITDA Margin: 14.4%
Op. Margin: 8.2%
Net Margin: 12.0%

Op. margin of 8.2% is up 48.2% YoY — cost efficiency is improving. Net margin at 12.0% and gross margin of 31.5% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 32.2x
P/S Ratio: 1.6x
P/B Ratio: 1.9x

At 32.2x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.6x and P/B of 1.9x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $11.63B
Cash: $464.30M
Long-Term Debt: $3.65B
Book Value: $5.84B
D/E Ratio: 0.6
Debt/EBITDA: 14.9

With $11.63B in assets and $3.65B in long-term debt, D/E is 0.6and book value is $5.84B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $195.10M
TTM Free Cash Flow: $439.20M
FCF Margin: 6.6%
FCF / Net Income: 1.3

TTM FCF of $439.20M on $195.10M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 16% — a weakening trend.